Santhera nears cash break-even as AGAMREE gains traction, Edison says
Santhera nears cash break-even as AGAMREE gains traction, Edison says Proactive uses images sourced from Shutterstock Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0), the Swiss rare-disease drugmaker, is closing in on a financial turning point, according to research house Edison. In a QuickView note published on …